12CEntitlement to botulinum toxin pharmaceutical benefits for treatment of urinary incontinence due to idiopathic overactive bladder

12C Entitlement to botulinum toxin pharmaceutical benefits for treatment of urinary incontinence due to idiopathic overactive bladder

(1) This section applies to eligible patients receiving treatment of urinary incontinence due to idiopathic overactive bladder who: (a) are aged 18 years or more; and (b) are willing and able to self‑catheterise; and (c) have experienced at least 14 episodes of urinary incontinence per week prior to commencement of treatment with a botulinum toxin pharmaceutical benefit; and (d) have been inadequately controlled by therapy involving at least two alternative anti‑cholinergic agents. (2) A person mentioned in subsection (1) is not eligible to receive a botulinum toxin pharmaceuetical benefit under this Special Arrangement if the person does not achieve a 50% or greater reduction from baseline in urinary incontinence episodes 6‑12 weeks after the first treatment.